08.13.07
Roche has filed an IND with the FDA for a Genmab antibody developed under the companies' collaboration. Genmab will receive a milestone payment from Roche.
Under the agreement with Roche, Genmab uses its antibody expertise and development capabilities to create human antibodies to a range of disease targets identified by Roche. Genmab receives milestone and royalty payments based on successful products. Genmab may also obtain rights to develop products based on disease targets identified by Roche. Genmab stands to receive as much as $100 million plus royalties if all goals are reached.
"This will be the second antibody produced under our collaboration with Roche to enter the clinic and Genmab's seventh antibody to enter clinical development overall," said Lisa N. Drakeman, Ph.D., chief executive officer of Genmab. "Our partnership with Roche continues to bear fruit and add value to Genmab's expanding product pipeline."
Under the agreement with Roche, Genmab uses its antibody expertise and development capabilities to create human antibodies to a range of disease targets identified by Roche. Genmab receives milestone and royalty payments based on successful products. Genmab may also obtain rights to develop products based on disease targets identified by Roche. Genmab stands to receive as much as $100 million plus royalties if all goals are reached.
"This will be the second antibody produced under our collaboration with Roche to enter the clinic and Genmab's seventh antibody to enter clinical development overall," said Lisa N. Drakeman, Ph.D., chief executive officer of Genmab. "Our partnership with Roche continues to bear fruit and add value to Genmab's expanding product pipeline."